Current and Emerging Therapies for Eosinophilic Esophagitis (EoE): A Comprehensive Review
Eosinophilic Esophagitis (EoE) is a chronic, immune-mediated disorder that is characterized by symptoms of esophageal dysfunction and the presence of increased eosinophils in the esophageal mucosa. It is becoming increasingly prevalent among children and adults and its pathogenesis arises from the c...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/17/6/753 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849432538867564544 |
|---|---|
| author | Brooke G. Musburger Maria Gonzalez Echeandia Elias L. Suskind David L. Suskind Hengqi Betty Zheng Dominique Mark |
| author_facet | Brooke G. Musburger Maria Gonzalez Echeandia Elias L. Suskind David L. Suskind Hengqi Betty Zheng Dominique Mark |
| author_sort | Brooke G. Musburger |
| collection | DOAJ |
| description | Eosinophilic Esophagitis (EoE) is a chronic, immune-mediated disorder that is characterized by symptoms of esophageal dysfunction and the presence of increased eosinophils in the esophageal mucosa. It is becoming increasingly prevalent among children and adults and its pathogenesis arises from the complex interaction of genetic predisposition and environmental triggers, both which contribute to esophageal inflammation. Current societal guidelines recommend the use of proton pump inhibitors, topical steroids, and dietary interventions such as elimination diets as first-line treatments, however, the recent approval of Dupliumab has provided an additional therapeutic avenue. There are a number of investigational biologic agents targeting other immune pathways which are making their way through the pipeline of pharmacologic options in treating this chronic disorder. |
| format | Article |
| id | doaj-art-c57d01b553de4834a2f65e2f6166d9ee |
| institution | Kabale University |
| issn | 1999-4923 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj-art-c57d01b553de4834a2f65e2f6166d9ee2025-08-20T03:27:21ZengMDPI AGPharmaceutics1999-49232025-06-0117675310.3390/pharmaceutics17060753Current and Emerging Therapies for Eosinophilic Esophagitis (EoE): A Comprehensive ReviewBrooke G. Musburger0Maria Gonzalez Echeandia1Elias L. Suskind2David L. Suskind3Hengqi Betty Zheng4Dominique Mark5Division of Pediatric Gastroenterology, Seattle Children’s Hospital, Seattle, WA 98105, USADivision of Pediatric Gastroenterology, Seattle Children’s Hospital, Seattle, WA 98105, USASchool of Life Sciences, Arizona State University, 427 E Tyler Mall, Tempe, AZ 85281, USADivision of Pediatric Gastroenterology, Seattle Children’s Hospital, Seattle, WA 98105, USADivision of Pediatric Gastroenterology, Seattle Children’s Hospital, Seattle, WA 98105, USADepartment of Pharmacy, Seattle Children’s Hospital, Seattle, WA 98105, USAEosinophilic Esophagitis (EoE) is a chronic, immune-mediated disorder that is characterized by symptoms of esophageal dysfunction and the presence of increased eosinophils in the esophageal mucosa. It is becoming increasingly prevalent among children and adults and its pathogenesis arises from the complex interaction of genetic predisposition and environmental triggers, both which contribute to esophageal inflammation. Current societal guidelines recommend the use of proton pump inhibitors, topical steroids, and dietary interventions such as elimination diets as first-line treatments, however, the recent approval of Dupliumab has provided an additional therapeutic avenue. There are a number of investigational biologic agents targeting other immune pathways which are making their way through the pipeline of pharmacologic options in treating this chronic disorder.https://www.mdpi.com/1999-4923/17/6/753eosinophilic esophagitisEoEEGID |
| spellingShingle | Brooke G. Musburger Maria Gonzalez Echeandia Elias L. Suskind David L. Suskind Hengqi Betty Zheng Dominique Mark Current and Emerging Therapies for Eosinophilic Esophagitis (EoE): A Comprehensive Review Pharmaceutics eosinophilic esophagitis EoE EGID |
| title | Current and Emerging Therapies for Eosinophilic Esophagitis (EoE): A Comprehensive Review |
| title_full | Current and Emerging Therapies for Eosinophilic Esophagitis (EoE): A Comprehensive Review |
| title_fullStr | Current and Emerging Therapies for Eosinophilic Esophagitis (EoE): A Comprehensive Review |
| title_full_unstemmed | Current and Emerging Therapies for Eosinophilic Esophagitis (EoE): A Comprehensive Review |
| title_short | Current and Emerging Therapies for Eosinophilic Esophagitis (EoE): A Comprehensive Review |
| title_sort | current and emerging therapies for eosinophilic esophagitis eoe a comprehensive review |
| topic | eosinophilic esophagitis EoE EGID |
| url | https://www.mdpi.com/1999-4923/17/6/753 |
| work_keys_str_mv | AT brookegmusburger currentandemergingtherapiesforeosinophilicesophagitiseoeacomprehensivereview AT mariagonzalezecheandia currentandemergingtherapiesforeosinophilicesophagitiseoeacomprehensivereview AT eliaslsuskind currentandemergingtherapiesforeosinophilicesophagitiseoeacomprehensivereview AT davidlsuskind currentandemergingtherapiesforeosinophilicesophagitiseoeacomprehensivereview AT hengqibettyzheng currentandemergingtherapiesforeosinophilicesophagitiseoeacomprehensivereview AT dominiquemark currentandemergingtherapiesforeosinophilicesophagitiseoeacomprehensivereview |